Jakub Svoboda, MD, University of Pennsylvania, Philadelphia, PA, highlights the focus on improving CR rates in patients treated with CAR T-cell therapy as strong persistence and duration of response have already been achieved. Recorded at the 2019 National Cancer Research Institute (NCRI) Annual Cancer Conference, in Glasgow, UK.
For more information about the NCRI Cancer Conference, visit https://conference.ncri.org.uk.